Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for CB-011 in Multiple myeloma. The expected timing is based on the latest available company guidance and may change.
CaMMouflage trial. 3/29/23- First patient dosed. Enrollment ongoing in dose level 3. 11/3/25- First clinical data reported. Initiate dose expansion by YE 2025. Share dose expansion data in 2026. 11/12/25:- CaMMouflage Ph1 data reiterated; recommended dose 450M cells; dose expansion data expected 2026. 02/04/26:- CaMMouflage Ph1 late-breaking Tandem 2026 oral presentation of dose escalation clinical and translational data. 03/05/26:- Tandem 2026 oral presentation showed new translational data; CaMMouflage Ph1 dose expansion and longer follow-up data expected 2026. 03/31/26:- FDA granted RMAT for CB-011 r/r MM. Initial dose expansion and longer follow-up data expected 2026. 05/07/26:- CaMMouflage Ph1 enrolling BCMA-naïve and BCMA-exposed r/r MM; longer follow-up and initial expansion data expected 2026. 05/12/26:- CaMMouflage Ph1 longer follow-up to be presented at EHA 2026 on June 14, 2026. 06/11/26:- Longer follow-up shared; initial Ph1 dose expansion data expected in H2 2026. 08/13/26:- CaMMouflage Ph1 reported 92% ORR and 83% CR or better. Initial expansion and longer follow-up data will be reported in H2 2026.
Verification
Confirm timing and program details against the company announcement or filing.